Qrono

Executive Summary

Qrono is a private, preclinical-stage biotechnology company founded in 2019, headquartered in San Francisco. The company focuses on modulating antigen-presenting cells (APCs) to enhance vaccine efficacy and develop curative treatments for autoimmune diseases. By targeting APCs, Qrono aims to improve immune responses in vaccination and re-establish tolerance in autoimmunity. Operating as a research and development organization, Qrono has not yet disclosed any drug candidates, clinical trials, or funding rounds, reflecting its early stage of development. The company's approach is innovative but faces typical risks associated with preclinical biotech, including scientific validation, regulatory hurdles, and capital requirements. Given the limited public information, Qrono's current profile suggests it is still in the discovery phase, with no published data or partnerships. The company's success hinges on advancing its APC-modulating platform into preclinical models and securing funding to support IND-enabling studies.

Upcoming Catalysts (preview)

• Q4 2026Publication of Preclinical Proof-of-Concept Data40% success
• Q2 2027Series A Financing Round30% success
• TBDStrategic Partnership or Licensing Deal20% success